Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis (ICARuS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
The Cleveland Clinic
Brigham and Women's Hospital
University of Miami
University of Pittsburgh
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01815359
First received: March 13, 2013
Last updated: May 18, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2018
  Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)